drugset / Trial / NCT01471132

Sequential HIPEC of Oxaliplatin and Paclitaxel for Gastric Cancer Patients With Peritoneum Metastasis

NCT01471132 ↗

Phase 2 Unknown 20 enrolled Peking University
NaSingle-groupOpen-labelTreatment

Summary

The recurrence and metastasis of peritoneum is always the lethal consequence for gastric cancer patients, and there is no effective therapy until now. It has been reported by Dr.Fujimoto that intraperitoneal chemotherapy plus hyperthermic therapy, which called hyperthermic intraperitoneal chemotherapy (HIPEC), can eliminate and suppress the free cancer cells and tiny metastasis in abdomen. Refer to the experience of systematic chemotherapy, HIPEC with combination regimen would have a brighter prospect. In this study, the investigators would use Oxaliplatin and paclitaxel sequent as HIPEC regimen. The safety and overall survival would be observed and evaluated.

Timeline

Start
2011-09
Primary completion
2013-09
Completion
2015-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxaliplatin Small molecule 345 mg/m2 Other
Subject Paclitaxel Small molecule 260 mg/m2 Other

Indications